Biondvax Pharma Ads (BVXV) 3.60 $BVXV Professor Shai

New Post Public Reply Private Reply Replies (0) Message Board

Sep 20, 2016 at 9:12 PM

Biondvax Pharma Ads (BVXV) 3.60 $BVXV

Professor Shai Ashkenazi Appointed to BiondVax's Scientific Advisory Board
PR Newswire - Wed Sep 07, 8:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing a vaccine against current and future seasonal and pandemic influenza strains, is pleased to announce the appointment of Professor Shai Ashkenazi to its Scientific Advisory Board (SAB).
BVXV: 3.60 (-0.05)

BiondVax Announces Second Quarter 2016 Financial Results and Update
PR Newswire - Thu Aug 18, 3:07PM CDT
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV; TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing a vaccine against current and future seasonal and pandemic influenza strains, today announced its second quarter 2016 financial results ended June 30, 2016 and provided a business update.
BVXV: 3.60 (-0.05)

BiondVax Invited to WHO Influenza Vaccine Meeting
PR Newswire - Wed Aug 10, 7:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that it has been invited to participate in the 'Eighth WHO meeting on the development of influenza vaccines that induce broadly protective and long-lasting immune responses'. The meeting will be held in Chicago, IL on August 23 and 24, 2016.
BVXV: 3.60 (-0.05)

BiondVax CEO to Present Universal Flu Vaccine Technology at BIO International Convention
PR Newswire - Thu Jun 02, 7:17AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will be presenting and participating in a panel discussion at BIO International Convention in San Francisco.
BVXV: 3.60 (-0.05)

BiondVax Announces First Quarter 2016 Financial Results and Update
PR Newswire - Tue May 31, 3:01PM CDT
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases today announced its first quarter 2016 financial results ended March 31, 2016 and provided a business update. The Company's leading product, M-001, is a universal flu vaccine.
BVXV: 3.60 (-0.05)

BiondVax to Present Tomorrow at Joseph Gunner Pioneers 2016 Conference
PR Newswire - Wed May 04, 8:29AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will be attending the Joseph Gunnar Pioneers 2016 conference in New York City.
BVXV: 3.60 (-0.05)

BiondVax Announces Fourth Quarter and Full Year 2015 Financial Results and Update
PR Newswire - Wed Apr 27, 4:18PM CDT
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its fourth quarter and full year financial results ended December 31, 2015 and provided a business update.
BVXV: 3.60 (-0.05)

Biondvax's Universal Flu Vaccine Receives Additional US Patent
PR Newswire - Wed Jan 27, 6:00AM CST
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) developer of a Universal Flu Vaccine currently undergoing late-stage 2 clinical trials, announced today that its patent application in the United States titled "Multimeric Multi-Epitope Polypeptides in Improved Seasonal and Pandemic Influenza Vaccines" has completed examination and is allowed for issuance as a patent.
BVXV: 3.60 (-0.05)

BiondVax Receives Approval for a Patent for its Universal Flu Vaccine in Israel
PR Newswire - Mon Dec 21, 7:04AM CST
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) which is developing the Universal Flu Vaccine, announced today that its patent application in Israel on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines (a universal flu vaccine), was accepted.
BVXV: 3.60 (-0.05)

BiondVax to Bring Long-Awaited Universal Flu Vaccine to the Market
CNW Group - Thu Dec 03, 9:00AM CST
With various advancements being made in preventative care, cancer treatment, HIV and AIDS research and aging, it's hard to believe that the flu is still a serious health threat. However, influenza, an acute respiratory tract infection, can still prove life threatening for the elderly and those with weak immune systems. A common misconception is that influenza is merely a bad cold. Yet, while the flu may produce similar symptoms to the common cold like coughing or nasal congestion, the World Health Organization reports that 250,000 to 500,000 individuals die annually due to the flu, with the majority of those deaths caused pulmonary and cardiovascular complications. Every year, 36,000 people die in the United States and more than 200,000 are hospitalized due to the flu, along with an annual economic burden of over $25 billion.
BVXV: 3.60 (-0.05)

Patent Approval for BiondVax: BiondVax Receives Approval for Patent in Korea for its Universal Flu Vaccine
PR Newswire - Tue Nov 17, 7:54AM CST
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) which is developing the Universal Flu Vaccine, announced today that its main patent on the Multimeric Multi-Epitope Polypeptide Influenza Vaccines family, was granted in Korea.
BVXV: 3.60 (-0.05)

BiondVax Announces Third Quarter 2015 Financial Results and Update
PR Newswire - Mon Nov 09, 6:00AM CST
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BVXV), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its financial results for the third quarter of 2015 and provided a business update.
BVXV: 3.60 (-0.05)

BiondVax Pharmaceuticals Ltd. Selects Cytovance(R) Biologics Inc. for the Manufacturing of M-001 the Universal Flu Vaccine for Phase III Clinical Trials
Marketwired - Tue Nov 03, 4:00AM CST
CytovanceÂ® Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE: BVXV) (NASDAQ: BVXV), a biopharmaceutical company, based in Ness Ziona Israel.
BVXV: 3.60 (-0.05)

BiondVax Announces Successful Recruitment of the First Participants in a Phase IIb Clinical Trial in Europe with its Universal Flu Vaccine: Multimeric M-001
PR Newswire - Wed Oct 21, 6:59AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that it has successfully recruited the first two participants in this trial, BVX-007. The trial is being conducted in Budapest, Hungary at the St Istvan and St Lazslo Hospital, as well as additional satellite sites in Hungary, together with the partners from the UNISEC European Consortium.
BVXV: 3.60 (-0.05)

BiondVax to Present on October 8 at the Aegis Growth Conference
PR Newswire - Tue Oct 06, 3:30PM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that BiondVax's CEO, Dr. Ron Babecoff, will participate in the Aegis Growth Conference, taking place at The Encore at Wynn Hotel in Las Vegas, NV from October 7-9, 2015.
BVXV: 3.60 (-0.05)

BiondVax Establishes Capability for the Manufacture of Clinical Grade Universal Flu Vaccine for Phase III Clinical Trials
PR Newswire - Thu Oct 01, 6:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that it has entered into a Development and Manufacturing Agreement for the production of clinical batches of its universal flu vaccine, M-001, with Cytovance Biologics Inc., a Contract Manufacturing Organization (CMO), based in Oklahoma, USA.
BVXV: 3.60 (-0.05)

BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak
PR Newswire - Wed Sep 30, 6:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium.
BVXV: 3.60 (-0.05)

BiondVax to Present on September 10 at the Rodman & Renshaw Global Investment Conference
PR Newswire - Tue Sep 08, 12:00AM CDT
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) today announced that the Company's CEO, Dr. Ron Babecoff, will participate in the Rodman & Renshaw 17th Annual Global Investment Conference, taking place at the St. Regis hotel in New York from September 8-10, 2015.
BVXV: 3.60 (-0.05)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TURNSON: A New Twist in the Drinking Game Arena

TURNSON Raises the Bar for Social Fun When was the last time a new drinking game actually turned heads? Well, meet TURNSON, the fresh contender coming out of a tiny town in Louisiana. Thanks to a couple of inventive minds, this game aims to redefine how adults bond at parties. It's got the ingredients to stir up some excitement at social gatherings, parties, and wherever...

AIM-T1 Wins at CES 2027, Paving AI in Electronics

AIM-T1: A Game-Changer for Electronics Manufacturing You ever wonder how a single gizmo could shake up the entire electronics manufacturing world? Well, A.I.Matics' AIM-T1 has done just that by snagging two coveted CES Innovation Awards for 2027. In the cutthroat arenas of Artificial Intelligence and Construction & Industrial Tech, this platform's getting the spotlight...

TCL Tablets Arrive on BestBuy.com: What It Means

Go Big or Go Home: TCL's Bold Move TCL just dropped a little bombshell that's gonna ripple through the electronics retail market—its tablets and smartphones are now bright and shiny on BestBuy.com. It's like standing at the craps table and before you know it, the stakes have just doubled. Why? Best Buy ain't some hole-in-the-wall spot. It's the premium electronics...

Stocks Jump Ahead of Critical Inflation Reports

Stocks Lift as Wall Street Awaits Inflation Data Every trader's favorite game—speculation—returns as major U.S. stock benchmarks kick off Monday with some gusto. The S&P 500, Nasdaq Composite, Dow Jones Industrial Average, and Russell 2000 all saw gains in the early morning session, signaling positive vibes across the board. Numbers don't lie, folks: The S&P climbed...

AWS Boosts Agilix's AI Education in Sierra Leone

Agilix Labs' Landmark Leap with AWS Just when you think you've got the grip on global education dynamics, a new wave hits your shores, this time courtesy of Agilix Labs and AWS. Agilix Labs snagged a grant from Amazon Web Services, carving a path that blends AI with educational equity in Sierra Leone. Now, if that doesn’t prick up investor ears or yank a few...

Gold Prices Climb; Miners Stick to Guidance Amid Stress

Wham, pow! Gold's climbing up to the skies again. As if the shiny stuff needed more fanfare, there it is, breaking above $4,000 an ounce. Remember when it couldn't hold a candle to $1,500? Now the December gold futures are planting themselves firmly at $4,124.10. That's a healthy leap from Friday's close by $49.20. How about that for a head-turner? Miners Holding the Line...

Mattamy Homes' Winning Streak: Top Workplace Once Again

Mattamy Homes Strikes Gold Again in Tucson Amidst the desert landscapes of Tucson, Mattamy Homes has etched its name in the sands of workplace excellence yet again. This 2026 accolade marks the second consecutive year the company clinched the Tucson Top Workplaces title, conferred by Energage. For those keeping score, that's not just a streak—it's a testament to a work...

Huawei's 2026 Leap in Gartner Magic Quadrant Recognition

China's Telecom Giant Steps Up Globally Gartner's all about benchmarks and bragging rights in the tech world, and brother, Huawei just grabbed a major piece of that spotlight in 2026. They've snagged a spot in the coveted Leaders Quadrant of the Gartner Magic Quadrant for Infrastructure Platform Consumption Services. Now, why should folks with skin in the game care?...

JobPlanner Advances Mobile Tech for Construction Crews

JobPlanner's Attempt to Tackle a Labor Crunch Construction's been walking on the tightrope for a while now. With a workforce that's graying like a couple of old Neanderthals and fewer fresh faces showing up on site, contractors are sweating bullets. Today, in the thickets of Austin's business landscape, JobPlanner rolled out an expanded Mobile Field Management toolkit,...

Valmet Expands Board Maker Deal in Asia With New Line

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...